Benefit of adjuvant, but not concurrent, temozolomide for IDH-mutant anaplastic astrocytoma

Hikaru Sasaki

研究成果: Comment/debate › 査読

2 被引用数 (Scopus)

ASJC Scopus subject areas

@article{2d5dad3eaa5b4f42afabcb22373cebc6,

title = "Benefit of adjuvant, but not concurrent, temozolomide for IDH-mutant anaplastic astrocytoma",

author = "Hikaru Sasaki",

year = "2021",

month = jun,

doi = "10.1016/S1470-2045(21)00154-6",

language = "English",

volume = "22",

pages = "743--744",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "6",

}

TY - JOUR

T1 - Benefit of adjuvant, but not concurrent, temozolomide for IDH-mutant anaplastic astrocytoma

AU - Sasaki, Hikaru

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85106602239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106602239&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(21)00154-6

DO - 10.1016/S1470-2045(21)00154-6

M3 - Comment/debate

C2 - 34000247

AN - SCOPUS:85106602239

SN - 1470-2045

VL - 22

SP - 743

EP - 744

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 6

ER -